Stephen P. MacMillan worked at Stryker Corporation from June 2003, eventually becoming CEO in January 2005 and Chairman in 2010. He came from a strong background, previously holding significant roles at Pharacia and Johnson & Johnson. His business decisions influenced...
Stephen P. MacMillan worked at Stryker Corporation from June 2003, eventually becoming CEO in January 2005 and Chairman in 2010. He came from a strong background, previously holding significant roles at Pharacia and Johnson & Johnson. His business decisions influenced Stryker’s growth during a key period. He received a notable stock option grant of 1 million shares in 2006, showcasing the company’s trust in his leadership. In 2011, his compensation reached over $1.1 million, which included a performance-related bonus. However, his journey hit a bump when he resigned on February 8, 2012, walking away with a severance package totaling $5.5 million. Even after leaving, he held shares in Boston Scientific worth between $285,000 in May 2020 and approximately $655,680 by October 2024. MacMillan’s experience reflects his strategic skills and the volatility of executive roles in major corporations.